Randomization and Masking
SQUAMOUS CELL CARCINOMA, CAVITY
Patients with operable, histologically documented, squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx were randomized 3:3:1:3 among C and olaparib (arm A), monotherapy with O (arm B), no treatment (arm C), or combination with D and olaparib (arm D), before surgery. Patients had surgery on day 23 to day 29. Patients were selected irrespectively of mutation status (somatic and/or germline) or other biomarkers.